T1	Participants 396 425	CAS and prostate-only (PO) RT
T2	Participants 611 782	ligibility included localized prostate cancer with an elevated prostate-specific antigen (PSA) < or = 100 ng/mL and an estimated risk of lymph node (LN) involvement of 15%
T3	Participants 825 852	1,323 patients were accrued
